Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function. The current clinical role for the DCB is in de-novo disease where stent implantation is not ideal and in the realm of in-stent restenosis. Treatment with DCB may facilitate a shorter duration of dual antiplatelet therapy compared with drug eluting stent use. DCB use facilitates the treatment of coronary stenosis whilst avoiding permanent vascular implants.